Blog
Daily evidence-led peptide research, regulatory news, expert digest and explainers. Every claim sourced; no AI tells.
Page 16
Retatrutide: Lilly plans FDA filing in 2027
New TRIUMPH data give Lilly the evidence to file an FDA application for retatrutide in Q1 2027. The cardiovascular outcomes question remains open.
Semaglutide for postpartum prediabetes
A Belgian trial is testing whether once-weekly semaglutide can stop postpartum prediabetes after gestational diabetes from becoming type 2 diabetes.
Semaglutide proteomics: 16 studies reviewed
A 2026 review of 16 proteomics studies maps what semaglutide does to proteins across human and animal tissues, from fat metabolism to cardiac remodelling.
What proteomics reveals about semaglutide
A 2026 review pooled 16 proteomics studies of semaglutide in humans and animals to map which proteins and pathways the drug shifts, and how much to trust it.
Semaglutide after GDM: the SERENA trial
A Belgian RCT tests semaglutide 1 mg in 252 women with postpartum prediabetes after gestational diabetes to see if it can prevent type 2 diabetes.
Tirzepatide: what real-world users report
A 2026 real-world survey of 151 US physicians and 199 patients found high satisfaction with once-weekly tirzepatide for obesity, plus clear limits.
Tirzepatide: real-world survey 2026
A 2026 survey of 151 physicians and 199 patients found over 90% would recommend tirzepatide, and 78.5% of physicians rated obesity outcomes a success.
BPC-157 UK import rules for personal use
UK law exempts personal imports of medicines from the manufacturer's licence rule. Selling or advertising BPC-157 in the UK is a different question entirely.
Bremelanotide stability: 8 degradants
A July 2026 analytical study characterized eight degradation products of bremelanotide acetate and predicted which chiral centers epimerize under stress.
BPC-157 UK import rules: the MHRA position
BPC-157 has no UK marketing authorisation and no approved import route for personal use. Here is what the MHRA framework and border rules mean.
What GLP-1 labels say is worth tracking
The semaglutide and tirzepatide labels name specific things to monitor on a GLP-1, and the list is not the one a weight graph suggests.
What to track on a peptide protocol
Structured logging of dose schedule, injection sites, side effects, and body metrics helps clinicians manage GLP-1 and peptide protocols effectively.